NRx Pharmaceuticals, Inc.
NASDAQ:NRXPBiotechnology
+$0.06 today
- Market cap
- $124.12M
- Beta
- 2.19
- P/E (TTM)
- -5.3
- EPS (TTM)
- -$0.76
Volume 2.09M
Average 1.27M
NRXP Short-term Debt
Borrowings and the current portion of long-term debt due within one year.
NRx Pharmaceuticals, Inc.NASDAQ: NRXP
Short-term Debt · Q1 FY2026 · quarter ended Mar 2026
Short-term debt remains negative
Q1 FY2026 short-term debt was $0, compared with $8.4M a year earlier.
Context
- Short-term debt amounted to 0.0% of total assets at the end of Q1 FY2026, down 110.6 pp from a year earlier.
- Short-term debt increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether short-term debt keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Debt history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Short-term Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 1.57M | -82.9% |
| FY2023 | 2023-12-31 | 9.16M | +18.9% |
| FY2022 | 2022-12-31 | 7.7M | +1387.1% |
| FY2021 | 2021-12-31 | 518K | — |
Short-term Debt vs competitors
How NRXP compares with its peers on the latest reported figures
- NRXP's Mar 2026 short-term debt of $0 is the 6th highest of the 9 companies compared; the peer median is $270.5K.
- Its year-over-year change of -100.0% is the 6th highest of 9, against a peer median of -60.1%.
- Short-term debt amounts to 0.0% of total assets for NRXP, versus a peer median of 0.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $32.23M | +31.8% | — | 24.5% | |
| Mar 2026 | $15.85M | +32.0% | +40.0% | 72.4% | |
| Mar 2026 | $1M | -25.7% | — | 1.8% | |
| Mar 2026 | $441K | +202.1% | -60.1% | 0.7% | |
| Mar 2026 | $100K | -94.6% | -60.2% | 0.5% | |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Jun 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding NRXP) | $270.5K | -60.1% | -60.1% | 0.6% | |
Competitors are the stored peer set for NRXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
Intrinsic Alpha fair value
Locked
Current Price
$2.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.